Asunto(s)
Hipertermia Inducida , Verrugas , Humanos , Crioterapia , Cinética , Resultado del Tratamiento , Verrugas/terapiaRESUMEN
Background: Large-scale retrospective studies of light/laser in treating nasal rosacea were lacking.Objective: The study was aimed to perform a decade retrospection of the patients with nasal rosacea who were treated with light/laser devices.Methods: A study between 2008 and 2017 was performed retrospectively. Categorization of rosacea type (erythema/telangiectasia, ET; papules/pustules, PP; rhinophyma, RP) was made according to the photographs. Device settings, treatment regimens and treatment sessions of light/laser facilities were summarized. Efficacy was evaluated using a grading scale.Results: In all, 807 patients received light/laser treatments. The subtypes of nasal rosacea were ET (n = 196), PP (n = 95), RP (n = 42), ET + PP (n = 334), ET + RP (n = 15), PP + RP (n = 88), and ET + PP + RP (n = 37). The lesions of ET or PP were mainly treated with noninvasive devices (Intense pulsed light, IPL; Dye pulse light, DPL; Dual wavelength laser system, DW) and those of RP were treated with the Fractional carbon dioxide (FCO2) laser. For the mixed subtypes, the general disposal orders of lesions were ET, PP, and later RP, and the fundamental orders of devices application were IPL, DPL, DW, and FCO2 laser. For all types of rosacea except for RP (2-4 sessions), most of the patients received 4-6 sessions of treatments. Of all subtypes of ET, PP, RP, ET + PP, ET + RP, PP + RP, and ET + PP + RP, the patients who achieved more than 50% improvement accounted for 74.5%, 58.3%, 83.3%, 69.2%, 73.3%, 61.4%, and 51.4%, respectively.Conclusion: The multiple, sequential light/laser devices can be safely used in nasal rosacea with various degrees efficacies based on different types.
Asunto(s)
Terapia por Láser , Fototerapia , Rosácea/terapia , Adolescente , Adulto , Anciano , Eritema/terapia , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Rinofima/terapia , Adulto JovenAsunto(s)
Análisis Mutacional de ADN/métodos , Displasia Ectodermal Anhidrótica Tipo 1/genética , Ectodisplasinas/genética , Secuenciación de Nucleótidos de Alto Rendimiento , Mutación , Glándulas Sebáceas/patología , Adulto , Pueblo Asiatico/genética , Biopsia , China , Displasia Ectodermal Anhidrótica Tipo 1/etnología , Displasia Ectodermal Anhidrótica Tipo 1/patología , Displasia Ectodermal Anhidrótica Tipo 1/terapia , Predisposición Genética a la Enfermedad , Folículo Piloso/trasplante , Humanos , Hiperplasia , Láseres de Gas , Terapia por Luz de Baja Intensidad/instrumentación , Masculino , Linaje , Fenotipo , Valor Predictivo de las Pruebas , Glándulas Sebáceas/efectos de la radiación , Resultado del TratamientoRESUMEN
Cardiac hypertrophy is an independent risk factor for cardiovascular disease and its subsequent progression to heart failure represents a major cause of morbidity and mortality in the world. CGA is an important component of Chinese herbal medicine, acting as an antioxidant, scavenging free radicals and preventing inflammation. This study found that with the pre-treatment of chlorogenic acid in Iso-induced neonatal rat myocytes, the levels of the hypertrophic markers, ANP, BNP and ß-MHC decreased. The nuclear translocation of NF-κB was blocked, whereas NF-κBIA, an inhibitor of NF-κB, was upregulated accordingly. And the level of the intracellular ROS was also reduced. These data reveal that chlorogenic acid may inhibit Iso-induced cardiac hypertrophy by attenuating NF-κB signaling pathway and suppressing ROS.
Asunto(s)
Cardiomegalia/prevención & control , Ácido Clorogénico/farmacología , Isoproterenol/farmacología , Miocitos Cardíacos/patología , Animales , Animales Recién Nacidos , Cardiomegalia/inducido químicamente , Células Cultivadas , Miocitos Cardíacos/metabolismo , FN-kappa B/fisiología , Transporte de Proteínas/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Especies Reactivas de Oxígeno/metabolismo , Transducción de Señal/efectos de los fármacosRESUMEN
OBJECTIVE: To observe the effects of Gu Fu Sheng Capsule ([symbol: see text] GFSC) on nitric oxide (NO) level and fibrinolytic activity in rabbits with glucocorticoid-induced ischemic necrosis of femoral head (GINFH) so as to explain the therapeutic mechanism of GFSC. METHODS: 48 rabbits were randomly divided into 4 groups: GFSC group A, Ma Shi Gu Pian ([symbol: see text] MSGP) group B, model group C, and control group D. The models of GINFH were produced by injection of glucocorticoid hormone for 8 weeks. From the 9th week, GFSC decoction was given to the rabbits of the group A (45 g x kg(-1) x d(-1)) and MSGP extract was given to the group B (0.17 g kg(-1) x d(-1)) and the same volume of normal saline to group C and D by intragastric infusion. The content of plasma nitric oxide (NO), and activities of tissue-type plasminogen activator (t-PA), and plasminogen activator inhibitor (PAI) were detected after the hormone was injected for 4 and 8 weeks and after the drugs were given for 4 weeks. RESULTS: Compared with the group D, the contents of NO and t-PA activity in the group C decreased significantly (P<0.01), but the activity of PAI increased significantly (P<0.01). Compared with the group C, the contents of NO and t-PA activity in the group A and B increased significantly (P<0.05), but the activity of PAI decreased significantly (P<0.05), with no significant difference between the two treatment groups (P>0.05). CONCLUSION: GFSC could increase the level of NO, protect endotheolial cells and improve fibrinolytic activity, which might be the mechanism of GFSC in curing GINFH.